At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 282 enrolled
Drug / intervention
JZP150 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Phase 2, 12-week Double-blind, Placebo-controlled, Randomized, Parallel-group Study of JZP150 for the Treatment of Posttraumatic Stress Disorder
In Brief
A Phase 2 clinical trial evaluating JZP150 and Placebo for Post Traumatic Stress Disorder. Completed, enrolled 282 participants across 52 sites.
Detailed Summary
This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP150 in the treatment of adult participants with post-traumatic stress disorder (PTSD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost Traumatic Stress Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartDec 2021
First PostedJan 2022
Primary CompletionDec 2023
TodayJul 2026
First PostedJan 5, 2022
Enrollment StartDec 29, 2021
Primary CompletionDec 5, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 4.5 years ago
Interventions
JZP150drug
Oral administration of JZP150 once daily in the morning
Placebodrug
Oral administration of placebo once daily in the morning